Entry Point Capital, LLC Biogen Inc. Transaction History
Entry Point Capital, LLC
- $112 Billion
- Q1 2024
A detailed history of Entry Point Capital, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 167 shares of BIIB stock, worth $37,509. This represents 0.03% of its overall portfolio holdings.
Number of Shares
167Holding current value
$37,509% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding BIIB
# of Institutions
1,047Shares Held
126MCall Options Held
1.37MPut Options Held
1.35M-
Vanguard Group Inc Valley Forge, PA16.6MShares$3.72 Billion0.07% of portfolio
-
Primecap Management CO Pasadena, CA16.2MShares$3.64 Billion2.65% of portfolio
-
Black Rock Inc. New York, NY14.1MShares$3.18 Billion0.07% of portfolio
-
State Street Corp Boston, MA6.75MShares$1.52 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.17MShares$1.16 Billion0.68% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $32.3B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...